Frontline iza-bren plus pembrolizumab yielded a 57.9% ORR in recurrent or metastatic HNSCC at 2.5 mg/kg, the dose chosen for phase 3 study.
News|Articles|September 30, 2024
Cisplatin/70 Gy IMRT Cemented as SOC for Nonsmoking p16+ Oropharyngeal Cancer
Author(s)Gina Mauro
Fact checked by: Ariana Pelosci
Experimental regimens did not cross the threshold to show superiority vs standard cisplatin plus 70 Gy radiation in those with HPV-associated oropharynx cancer.
Advertisement
Advertisement
The standard schedule of 70 Gy intensity-modulated radiation therapy (IMRT) plus cisplatin was not inferior to a deintensification Gy IMRT schedule or to a regimen using nivolumab (Opdivo) vs cisplatin in patients with p16-positive oropharyngeal cancer, according to results of a futility analysis of the phase 2/3 NRG-HN005 trial (NCT03952585) that was presented at the
Related to this article
At The Liver Meeting 2026, Daniel Q. Huang, MBBS, PhD, explained why cirrhosis-based HCC surveillance misses many patients with MASLD and how to find them.
At The Liver Meeting 2026, Hashem B. El-Serag, MD, MPH, discussed when patients with MASLD and F3 fibrosis may merit HCC surveillance.
At The Liver Meeting 2026, Pierre Gholam, MD, explained why liver tumor board plans often break down at implementation and how navigators can help.
Surveillance guidelines limited to cirrhosis may miss up to a third of patients with MASLD-related HCC, according to Daniel Q. Huang, MBBS, PhD.
Hashem B. El-Serag, MD, MPH, discussed fibrosis-based HCC surveillance, ultrasound limits, chemoprevention, and alcohol screening for patients with MASLD.
At The Liver Meeting® 2026, Andrew Moon, MD, MPH, discussed research revealing gaps between clinician and patient priorities in HCC treatment choice.
Pierre Gholam, MD, discussed how navigation, molecular profiling, and hub-and-spoke models can help liver tumor boards turn recommendations into care.
Advertisement
Advertisement